Malignant neoplasm. Malignant neoplasm, without specification of site
Conditions
Interventions
Intervention 1: Intervention group will receive Pentoxifylline (400 mg) three times a day. Intervention 2: Control group will receive exactly similar placebo capsules regarding shape, size and taste.
Treatment - Drugs
Placebo
Intervention group will receive Pentoxifylline (400 mg) three times a day.
Control group will receive exactly similar placebo capsules regarding shape, size and taste.
Sponsors
Vice chancellor for research, Isfahan University of medical sciences
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria are: 1. Histologic or cytologic proof evidencing cancers, 2. Incurable malignancy with a life expectancy=4 months, 3. Weight loss perceived by the patient as a problem, 4. Patient should be alert and mentally competent. Exclusion criteria are: 1. Affliction with edema or ascites, 2. Adrenal corticosteroids treatment (except for dexamethasone during chemotherapy) androgens, progestational agents, or other appetite stimulants within the previous month, 3. Brain metastases, 4. Pregnancy or lactation, 5. Mechanical obstruction of the alimentary tract, 6. Malabsorption, or intractable vomiting, 7. Poorly controlled hypertension or congestive heart failure.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Arm circumference. Timepoint: before and two months after intervention. Method of measurement: Meter calibrated.;Quality of life. Timepoint: before and two months after intervention. Method of measurement: SF-36 standard questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: during treatment. Method of measurement: clinical observation (nausea / vomiting / tachycardia). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactValiollah Mehrzad
Isfahan University of Medical Sciences
Outcome results
None listed